{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:12:36Z","timestamp":1793419956845,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:40:21Z","timestamp":1768336821000},"page":"23-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["How to Treat Carbapenem-Resistant Acinetobacter baumannii Infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Antonio","family":"Cascio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pipit\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/2049-632X.12125","article-title":"Acinetobacter baumannii: evolution of a global pathogen","volume":"71","author":"Antunes","year":"2014","journal-title":"Pathog Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics14010085","article-title":"The evolution of antimicrobial resistance in Acinetobacter baumannii and new strategies to fight it","author":"Scoffone","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.idc.2025.12.001_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.idc.2025.12.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2021.126722","article-title":"An overview of Acinetobacter baumannii pathogenesis: motility, adherence and biofilm formation","author":"Mea","year":"2021","journal-title":"Microbiol Res"},{"key":"10.1016\/j.idc.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","article-title":"Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals","volume":"48","author":"Ibrahim","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.idc.2025.12.001_bib8","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00004-25","article-title":"Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure","author":"Zhang","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3949\/ccjm.87a.19117","article-title":"Hospital-acquired and ventilator-associated pneumonia: diagnosis, management, and prevention","volume":"87","author":"Modi","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"10.1016\/j.idc.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis","volume":"79","author":"Mohd Sazlly Lim","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.idc.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/IDR.S163944","article-title":"Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality","volume":"11","author":"Mart\u00edn-Aspas","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.idc.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases Society of America guidance on the treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9061154","article-title":"Nebulized colistin in ventilator-associated pneumonia and tracheobronchitis: historical background, pharmacokinetics and perspectives","author":"Zhu","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.idc.2025.12.001_bib15","article-title":"Elucidating the pharmacokinetics\/pharmacodynamics of aerosolized colistin against multidrug-resistant acinetobacter baumannii and klebsiella pneumoniae in a mouse lung infection model","author":"Lin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jiph.2024.03.021","article-title":"Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: a systematic review and meta-analysis","volume":"17","author":"Son","year":"2024","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.idc.2025.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.idc.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/22221751.2020.1754133","article-title":"Colistin and its role in the era of antibiotic resistance: an extended review (2000\u20132019)","volume":"9","author":"El-Sayed Ahmed","year":"2020","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.idc.2025.12.001_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29132969","article-title":"Colistin: lights and shadows of an older antibiotic","author":"Diani","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.idc.2025.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1282464","article-title":"Utilizing liposomal encapsulation approach to address nephrotoxic challenges of colistimethate sodium through a preclinical study","author":"Mektrirat","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.idc.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s42770-023-01189-7","article-title":"The use of combination therapy for the improvement of colistin activity against bacterial biofilm","volume":"55","author":"Jalil","year":"2024","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.idc.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant acinetobacter baumannii: a prospective, observational study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idc.2025.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3947\/ic.2021.0007","article-title":"Colistin plus sulbactam or fosfomycin against carbapenem-resistant acinetobacter baumannii: improved efficacy or decreased risk of nephrotoxicity?","volume":"53","author":"Saelim","year":"2021","journal-title":"Infect Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/jac\/dkae253","article-title":"Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature","volume":"79","author":"Butler","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.12.001_bib29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to Metallo-B-lactamase-Producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae146","article-title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections","author":"Shields","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.12.001_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to Colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and stenotrophomonas maltophilia: a systematic review and meta-analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.idc.2025.12.001_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12040761","article-title":"Novel antimicrobial agents for gram-negative pathogens","author":"Karvouniaris","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.12.001_bib108","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","author":"Paterson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.12.001_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01627-24","article-title":"A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of acinetobacter spp","author":"Veeraraghavan","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/cjid\/2001136","article-title":"Sulbactam\u2013durlobactam: a novel antibiotic combination for the treatment of acinetobacter baumannii\u2013Calcoaceticus complex (ABC) hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","author":"Kabbara","year":"2025","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.idc.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae210","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01258-23","article-title":"In vitro activity of sulbactam-durlobactam against colistin-resistant and\/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals","author":"Iovleva","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.idc.2025.12.001_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01065-24","article-title":"Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK\/PD","author":"Ji","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf095","article-title":"Eravacycline as a last resort for difficult-to-treat resistant Acinetobacter baumannii infections in critically ill patients: three case reports with pharmacokinetic insights","author":"Mimram","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.idc.2025.12.001_bib46","unstructured":"Expert Committee on clinical use of antimicrobial and evaluation of antimicrobial resistance, Comprehensive evaluation of the clinical application of eravacycline, AVailable at: http:\/\/www.kangnaiyaopingjiawei.com\/?page_id=1751 (Accessed 10 July 2025), 2024."},{"key":"10.1016\/j.idc.2025.12.001_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117666","article-title":"Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii","author":"Garc\u00eda","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.idc.2025.12.001_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11101298","article-title":"Evaluating the efficacy of eravacycline and omadacycline against extensively drug-resistant Acinetobacter baumannii patient isolates","author":"Deolankar","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.12.001_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12071353","article-title":"Combinations of antibiotics effective against Extensively- and pandrug-resistant Acinetobacter baumannii patient isolates","author":"Halim","year":"2024","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.idc.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/phar.2908","article-title":"Combination eravacycline therapy for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii in patients with COVID-19: a case series","volume":"44","author":"Jackson","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.idc.2025.12.001_bib51","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/IDR.S515207","article-title":"Efficacy and safety of eravacycline combination therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in ICU patients: a retrospective Study","volume":"18","author":"Guo","year":"2025","journal-title":"Infect Drug Resist"},{"issue":"1","key":"10.1016\/j.idc.2025.12.001_bib65","first-page":"84","article-title":"Postoperative meningitis caused by multidrug-resistant pathogens: a case report","volume":"48","author":"Ak\u0131ll\u0131","year":"2025","journal-title":"New Microbiol"},{"key":"10.1016\/j.idc.2025.12.001_bib66","article-title":"Outcome of using intraventricular plus intravenous polymyxin B in post-neurosurgical patients with multi\/extensively drug-resistant gram-negative bacteria-induced intracranial infection","author":"Li","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.idc.2025.12.001_bib67","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2015.055","article-title":"Management of meningitis caused by multi drug-resistant acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate","author":"Schiaroli","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib68","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1469-0691.2009.03019.x","article-title":"Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review","volume":"16","author":"Khawcharoenporn","year":"2010","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.idc.2025.12.001_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/jscr\/rjae603","article-title":"Successful treatment of pan-drug resistant Acinetobacter baumannii meningitis\/ventriculitis following craniotomy and external ventricular drainage: a case report","author":"Gavrilovska","year":"2024","journal-title":"J Surg Case Rep"},{"key":"10.1016\/j.idc.2025.12.001_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clineuro.2016.12.006","article-title":"Variables determining mortality in patients with Acinetobacter baumannii meningitis\/ventriculitis treated with intrathecal colistin","volume":"153","author":"Ceylan","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.idc.2025.12.001_bib71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10096-024-04794-y","article-title":"Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study","volume":"43","author":"Hu","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib72","article-title":"Spinal arachnoiditis followed by intrathecal tigecycline therapy for central nervous system infection by extremely drug-resistant Acinetobacter baumannii","author":"Li","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.idc.2025.12.001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00518","article-title":"Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature","author":"Long","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.idc.2025.12.001_bib74","article-title":"A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii","author":"Fang","year":"2017","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.idc.2025.12.001_bib75","article-title":"A case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial acinetobacter : baumannii infection","author":"Deng","year":"2019","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.idc.2025.12.001_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s13756-018-0313-5","article-title":"Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report","author":"Guo","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.idc.2025.12.001_bib77","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.3888","article-title":"Combination treatment with intravenous tigecycline and intraventricular and intravenous colistin in postoperative ventriculitis caused by multidrug-resistant Acinetobacter baumannii","author":"Mizrahi","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.idc.2025.12.001_bib78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcrc.2018.07.025","article-title":"Intraventricular CNS treatment with colistin-tigecycline combination: a case series","volume":"47","author":"Tsolaki","year":"2018","journal-title":"J Crit Care"},{"issue":"5","key":"10.1016\/j.idc.2025.12.001_bib79","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10096-025-05077-w","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: a case report and literature review","volume":"44","author":"Wang","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13050453","article-title":"Role of cefiderocol in multidrug-resistant gram-negative central nervous system infections: real life experience and state-of-the-art","author":"Sollima","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.12.001_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using cefiderocol: a case report and literature review","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.12.001_bib82","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jac\/dkaf069","article-title":"Intraventricular injection of eravacycline in the treatment of carbapenem-resistant Acinetobacter baumannii meningitis: a case report","volume":"80","author":"Liu","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib83","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5194\/jbji-7-279-2022","article-title":"Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study","volume":"7","author":"Giannitsioti","year":"2022","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.idc.2025.12.001_bib84","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.12669\/pjms.40.11.8754","article-title":"Investigation of antibiotic resistance and biofilm formation ability of Acinetobacter baumannii isolated from urinary catheters","volume":"40","author":"Mumtaz","year":"2024","journal-title":"Pakistan J Med Sci"},{"key":"10.1016\/j.idc.2025.12.001_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jmii.2011.01.009","article-title":"Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients","volume":"44","author":"Kuo","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.idc.2025.12.001_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-017-1357-5","article-title":"Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant acinetobacter baumannii: a case report","author":"Tsachouridou","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.idc.2025.12.001_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7150\/jbji.42448","article-title":"Tigecycline versus colistin in the treatment of carbapenem-resistant Acinetobacter baumannii complex osteomyelitis","volume":"5","author":"Oliveira","year":"2020","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.idc.2025.12.001_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits","author":"Petraitis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib89","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: successful rescue therapy of extensively drug-resistant acinetobacter baumannii osteomyelitis with cefiderocol","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.12.001_bib90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/phar.2660","article-title":"Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: a case report","volume":"42","author":"Rose","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.idc.2025.12.001_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.idc.2025.12.001_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10706-y","article-title":"Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes","author":"Di Venanzio","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.idc.2025.12.001_bib93","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Craterocolla versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.12.001_bib94","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijantimicag.2018.07.016","article-title":"Overcoming challenges of treating extensively drug-resistant Acinetobacter baumannii bacteraemic urinary tract infection","volume":"52","author":"Chuang","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.12.001_bib95","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s15010-013-0507-y","article-title":"Colistin bladder instillation, an alternative way of treating multi-resistant acinetobacter urinary tract infection: a case series and review of literature","volume":"42","author":"Giua","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.idc.2025.12.001_bib96","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/jac\/dkac123","article-title":"In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract","volume":"77","author":"Fuchs","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.12.001_bib97","first-page":"175","article-title":"Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumannii","volume":"33","author":"Terzi","year":"2025","journal-title":"Infezioni Med Le"},{"key":"10.1016\/j.idc.2025.12.001_bib98","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.idc.2025.12.001_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13020356","article-title":"Acinetobacter baumannii complex infections: new treatment options in the antibiotic pipeline","author":"Arshad","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.idc.2025.12.001_bib100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2024.2326028","article-title":"Antibacterial agents active against gram negative Bacilli in phase I, II, or III clinical trials","volume":"33","author":"Paterson","year":"2024","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.idc.2025.12.001_bib102","article-title":"Evolutionary dynamics and research hotspots of phage applications against Acinetobacter baumannii infections from the past to the new era","volume":"16","author":"Jiang","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.idc.2025.12.001_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2150","article-title":"AI-driven drug discovery: exploring abaucin as a promising treatment against multidrug-resistant Acinetobacter baumannii","author":"Awan","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.idc.2025.12.001_bib104","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/acscentsci.2c00598","article-title":"An iterative approach guides discovery of the FabI inhibitor fabimycin, a late-stage antibiotic candidate with in vivo efficacy against drug-resistant gram-negative infections","volume":"8","author":"Parker","year":"2022","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.idc.2025.12.001_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020168","article-title":"\u03b2-Lactam\/\u03b2-Lactamase inhibitor combination antibiotics under development","author":"Katsarou","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.idc.2025.12.001_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00021-21","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2025.12.001_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105855","article-title":"Promising targets for immunotherapeutic approaches against Acinetobacter baumannii","author":"Buchhorn de Freitas","year":"2022","journal-title":"Microb Pathog"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:41:37Z","timestamp":1773780097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0891552025001060"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.12.001","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Treat Carbapenem-Resistant Acinetobacter baumannii Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}